Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary …
GT Ferguson, KF Rabe, FJ Martinez… - The Lancet …, 2018 - thelancet.com
Background Inhaled corticosteroids have been used in patients with chronic obstructive
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …
Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD
KF Rabe, FJ Martinez, GT Ferguson… - … England Journal of …, 2020 - Mass Medical Soc
Background Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting
muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive …
muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive …
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
LJ Nannini, P Poole, SJ Milan… - Cochrane Database of …, 2013 - cochranelibrary.com
Background Both long‐acting beta 2‐agonists and inhaled corticosteroids have been
recommended in guidelines for the treatment of chronic obstructive pulmonary disease …
recommended in guidelines for the treatment of chronic obstructive pulmonary disease …
[HTML][HTML] Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease
LJ Nannini, CJ Cates, TJ Lasserson… - The Cochrane database …, 2007 - ncbi.nlm.nih.gov
Background Long-acting beta-agonists and inhaled corticosteroids have both been
recommended in guidelines for the treatment of chronic obstructive pulmonary disease …
recommended in guidelines for the treatment of chronic obstructive pulmonary disease …
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind …
D Singh, A Papi, M Corradi, I Pavlišová, I Montagna… - The Lancet, 2016 - thelancet.com
Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
[HTML][HTML] Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic …
NA Hanania, DP Tashkin, EM Kerwin, JF Donohue… - Respiratory …, 2017 - Elsevier
Background The long-term safety and efficacy of a novel Co-Suspension™ Delivery
Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination …
Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination …
Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary …
DP Tashkin, SI Rennard, P Martin, S Ramachandran… - Drugs, 2008 - Springer
Background: The combination of an inhaled corticosteroid (ICS) and a long-acting
bronchodilator is recommended in the treatment of patients with chronic obstructive …
bronchodilator is recommended in the treatment of patients with chronic obstructive …
Once-daily single-inhaler triple versus dual therapy in patients with COPD
DA Lipson, F Barnhart, N Brealey… - … England Journal of …, 2018 - Mass Medical Soc
Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
LJ Nannini, P Poole, SJ Milan… - Cochrane Database …, 2013 - cochranelibrary.com
Background Both long‐acting beta 2‐agonists (LABA) and inhaled corticosteroids (ICS)
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …